Filgrastim - Amgen/Roche
Alternative Names: G-CSF; Gracinᵀᴹ; Gran; Granulocyte colony-stimulating factor - Amgen; Granulokine; Grasinᵀᴹ; KRN 8601; Meograstim; Neupogen; NupenLatest Information Update: 05 Nov 2023
At a glance
- Originator Kirin-Amgen
- Developer Amgen; Apricus Biosciences; Bristol-Myers Squibb; GSK; Kirin Holdings Company; Kirin-Amgen; University of Washington
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chemotherapy-induced damage; Neutropenia; Radiation injuries
- No development reported Breast cancer
Most Recent Events
- 15 Mar 2021 Filgrastim licensed to Clinigen for distribution in Africa and Asia
- 06 Jan 2020 No development reported - Phase-I/II for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT00041470)
- 15 Nov 2019 Kyowa Kirin completes a phase II trial in Neutropenia in South Korea (NCT02685111)